Skip to main content

Articles

Page 20 of 77

  1. Disordered chromatin remodeling regulation has emerged as an essential driving factor for cancers. Imitation switch (ISWI) family are evolutionarily conserved ATP-dependent chromatin remodeling complexes, whic...

    Authors: Yanan Li, Han Gong, Pan Wang, Yu Zhu, Hongling Peng, Yajuan Cui, Heng Li, Jing Liu and Zi Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:346
  2. Fibroblast growth factors (FGFs) and their receptors (FGFRs) play critical roles in many biological processes and developmental functions. Chromosomal translocation of FGFRs result in the formation of chimeric...

    Authors: Lingfeng Chen, Yanmei Zhang, Lina Yin, Binhao Cai, Ping Huang, Xiaokun Li and Guang Liang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:345
  3. Mounting evidence indicates that vitamin C has the potential to be a potent anti-cancer agent when administered intravenously and in high doses (high-dose IVC). Early phase clinical trials have confirmed safet...

    Authors: Franziska Böttger, Andrea Vallés-Martí, Loraine Cahn and Connie R. Jimenez
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:343
  4. Although thousands of long noncoding RNAs (lncRNAs) have been annotated, only a few lncRNAs have been characterized functionally. In this study, we aimed to identify novel lncRNAs involved in the progression o...

    Authors: Donglan Huang, Ke Zhang, Wenying Zheng, Ruixin Zhang, Jiale Chen, Nan Du, Yuanyuan Xia, Yan Long, Yixue Gu, Jianhua Xu and Min Deng
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:342
  5. Histone epigenetic modification disorder is an important predisposing factor for the occurrence and development of many cancers, including colorectal cancer (CRC). The role of MYSM1, a metalloprotease that deu...

    Authors: Xu Chen, Wei Wang, Yufang Li, Yi Huo, Han Zhang, Fan Feng, Wenjin Xi, Tianze Zhang, Jinjian Gao, Fan Yang, Siyi Chen, Angang Yang and Tao Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:341
  6. The zinc transporters Zrt- and Irt-related protein (ZIP/SLC39) are overexpressed in human tumors and correlate with poor prognosis; however, their contributions to carcinogenesis and chemoresistance in osteosa...

    Authors: Hongyu Li, Xin Shen, Mengjun Ma, Wenzhou Liu, Wen Yang, Peng Wang, Zhaopeng Cai, Rujia Mi, Yixuan Lu, Jiahao Zhuang, Yuhang Jiang, Yihui Song, Yanfeng Wu and Huiyong Shen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:340
  7. This article has been retracted. Please see the Retraction Notice for more detail: https://​doi.​org/​10.​1186/​s13046-021-02121-3

    Authors: Dian-Hui Xiu, Gui-Feng Liu, Shao-Nan Yu, Long-Yun Li, Guo-Qing Zhao, Lin Liu and Xue-Feng Li
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:339
  8. Epithelial ovarian cancer (EOC) harbors distinct genetic features such as homologous recombination repair (HRR) deficiency, and therefore may respond to poly ADP-ribose polymerase inhibitors (PARPi). Over the ...

    Authors: Mengyu Tao and Xia Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:338
  9. Long non-coding RNAs (lncRNAs) have been considered as one type of gene expression regulator for cancer development, but it is not clear how these are regulated. This study aimed to identify a specific lncRNA ...

    Authors: Erbao Bian, Xueran Chen, Li Cheng, Meng Cheng, Zhigang Chen, Xiaoyu Yue, Zhengwei Zhang, Jie Chen, Libo Sun, Kebing Huang, Cheng Huang, Zhiyou Fang, Bing Zhao and Jun Li
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:337
  10. Circular RNAs (circRNAs) have been shown to play vital biological functions in various tumors, including prostate cancer (PCa). However, the roles of circRNAs in the metastasis of PCa remain unclear. In the pr...

    Authors: Shiyu Mao, Wentao Zhang, Fuhan Yang, Yadong Guo, Hong Wang, Yuan Wu, Ruiliang Wang, Niraj Maskey, Zongtai Zheng, Cheng Li, Wenchao Ma, Junfeng Zhang, Yang Yan and Xudong Yao
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:336
  11. Glioblastoma (GBM) has a devastating median survival of only one year. Treatment includes resection, radiation therapy, and temozolomide (TMZ); however, the latter increased median survival by only 2.5 months ...

    Authors: Raghupathy Vengoji, Pranita Atri, Muzafar A. Macha, Parthasarathy Seshacharyulu, Naveenkumar Perumal, Kavita Mallya, Yutong Liu, Lynette M. Smith, Satyanarayana Rachagani, Sidharth Mahapatra, Moorthy P. Ponnusamy, Maneesh Jain, Surinder K. Batra and Nicole Shonka
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:335
  12. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Yanshan Ge, Xinhui Wang, Yali Guo, Junting Yan, Aliya Abuduwaili, Kasimujiang Aximujiang, Jie Yan and Minghua Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:334

    The original article was published in Journal of Experimental & Clinical Cancer Research 2021 40:42

  13. Recently, allogeneic natural killer (NK) cells have gained considerable attention as promising immunotherapeutic tools due to their unique biological functions and characteristics. Although many NK expansion s...

    Authors: Daun Jung, Young Seok Baek, In Jee Lee, Ki Yeon Kim, Heejoo Jang, Sohyun Hwang, Jieun Jung, Yong-wha Moon, Kyung-Soon Park, Yong-Soo Choi and Hee Jung An
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:333
  14. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Jie Wang, Xiaobo Yu, Huayi Peng, Yusheng Lu, Shuhui Li, Qing Shi, Jian Liu, Haiyan Dong, Vladimir Katanaev and Lee Jia
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:332

    The original article was published in Journal of Experimental & Clinical Cancer Research 2021 40:300

  15. Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and potentially permanent side effect of cancer treatment. For the management of OIPN, accurate diagnosis and understandin...

    Authors: Yang Yang, Bing Zhao, Xuejiao Gao, Jinbing Sun, Juan Ye, Jun Li and Peng Cao
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:331
  16. Circular RNAs (circRNAs) are a class of non-coding RNA that play critical roles in the development and pathogenesis of various cancers. The circRNA circGSK3B (hsa_circ_0003763) has been shown to enhance cell p...

    Authors: Xianxiong Ma, Hengyu Chen, Lei Li, Feng Yang, Chuanqing Wu and Kaixiong Tao
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:330
  17. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Hongtao Liu, Qing Zhang, Yinsen Song, Yibin Hao, Yunxia Cui, Xin Zhang, Xueying Zhang, Yue Qin, Guangzhao Zhu, Feng Wang, Jinghan Dang, Shanshan Ma, Yanting Zhang, Wenna Guo, Shenglei Li, Fangxia Guan…
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:329

    The original article was published in Journal of Experimental & Clinical Cancer Research 2021 40:287

  18. Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8...

    Authors: Jing Zhou, Qing Ji and Qi Li
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:328
  19. The efficacy of cancer immunotherapy largely depends on the tumor microenvironment, especially the tumor immune microenvironment. Emerging studies have claimed that microbes reside within tumor cells and immun...

    Authors: Jiayao Ma, Lingjuan Huang, Die Hu, Shan Zeng, Ying Han and Hong Shen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:327
  20. Despite the overall clinical success of immune checkpoint inhibitors (ICIs) for treating patients with solid tumors, a large number of patients do not benefit from this approach. Consequently, there is a need ...

    Authors: Christina Jensen, Neel I. Nissen, Claus S. Von Arenstorff, Morten A. Karsdal and Nicholas Willumsen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:326
  21. The small tyrosine kinase inhibitors (TKIs) subversively altered the lung cancer treatments, but patients will inevitably face the therapy resistance and disease recurrence. We aim to explore the potential rol...

    Authors: Kai Li, Zi-Yang Peng, Shan Gao, Qing-Shi Wang, Rui Wang, Xiang Li, Guo-Dong Xiao, Jing Zhang, Hong Ren, Shou-Ching Tang and Xin Sun
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:325

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2023 42:179

  22. Colorectal cancer (CRC) is one of the most frequent malignancy and a leading cause of cancer-related deaths. Therefore, further researches are required to identify novel and more effective diagnoses and to ide...

    Authors: Zeyin Rong, Zai Luo, Zhongmao Fu, Pengshan Zhang, Tengfei Li, Jianming Zhang, Zhonglin Zhu, Zhilong Yu, Qi Li, Zhengjun Qiu and Chen Huang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:324
  23. Patients with ovarian cancer often present at advanced stage and, following initial treatment success, develop recurrent drug-resistant disease. PARP inhibitors (PARPi) are yielding unprecedented survival bene...

    Authors: Camilla Coulson-Gilmer, Robert D. Morgan, Louisa Nelson, Bethany M. Barnes, Anthony Tighe, René Wardenaar, Diana C. J. Spierings, Helene Schlecht, George J. Burghel, Floris Foijer, Sudha Desai, Joanne C. McGrail and Stephen S. Taylor
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:323
  24. Histone acetylation and deacetylation seem processes involved in the pathogenesis of Ewing sarcoma (EwS). Here histone deacetylases (HDAC) class I were investigated.

    Authors: Oxana Schmidt, Nadja Nehls, Carolin Prexler, Kristina von Heyking, Tanja Groll, Katharina Pardon, Heathcliff D. Garcia, Tim Hensel, Dennis Gürgen, Anton G. Henssen, Angelika Eggert, Katja Steiger, Stefan Burdach and Günther H. S. Richter
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:322

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2022 41:7

  25. Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by uncontrolled proliferation of B-cells and severe immune dysfunction. Chemo(immuno)therapies (CIT) have traditionally aimed to r...

    Authors: Carol Moreno, Cecilia Muñoz, María José Terol, José-Ángel Hernández-Rivas and Miguel Villanueva
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:321
  26. Neuropathic pain is a clinically relevant adverse effect of several anticancer drugs that markedly impairs patients’ quality of life and frequently leads to dose reduction or therapy discontinuation. The poor ...

    Authors: Laura Micheli, Carmen Parisio, Elena Lucarini, Alessia Vona, Alessandra Toti, Alessandra Pacini, Tommaso Mello, Serena Boccella, Flavia Ricciardi, Sabatino Maione, Grazia Graziani, Pedro Miguel Lacal, Paola Failli, Carla Ghelardini and Lorenzo Di Cesare Mannelli
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:320

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2024 43:120

  27. Cancer stem cells (CSC) have been implicated in tumor progression. In ovarian carcinoma (OC), CSC drive tumor formation, dissemination and recurrence, as well as drug resistance, thus contributing to the high ...

    Authors: Marco Giordano, Alessandra Decio, Chiara Battistini, Micol Baronio, Fabrizio Bianchi, Alessandra Villa, Giovanni Bertalot, Stefano Freddi, Michela Lupia, Maria Giovanna Jodice, Paolo Ubezio, Nicoletta Colombo, Raffaella Giavazzi and Ugo Cavallaro
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:319
  28. SETD1A, a member of SET1/MLL family H3K4 methyltransferases, is involved in the tumorigenesis of numerous cancers. However, the biological role and mechanism of SETD1A in non-small cell lung cancer (NSCLC) rem...

    Authors: Rui Wang, Jian Liu, Kai Li, Ganghua Yang, Sisi Chen, Jie Wu, Xinming Xie, Hong Ren and Yamei Pang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:318
  29. SAMHD1 mediates resistance to anti-cancer nucleoside analogues, including cytarabine, decitabine, and nelarabine that are commonly used for the treatment of leukaemia, through cleavage of their triphosphorylat...

    Authors: Tamara Rothenburger, Dominique Thomas, Yannick Schreiber, Paul R. Wratil, Tamara Pflantz, Kirsten Knecht, Katie Digianantonio, Joshua Temple, Constanze Schneider, Hanna-Mari Baldauf, Katie-May McLaughlin, Florian Rothweiler, Berna Bilen, Samira Farmand, Denisa Bojkova, Rui Costa…
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:317
  30. FLVCR1-AS1 is a key regulator of cancer progression. However, the biological functions and underlying molecular mechanisms of pancreatic cancer (PC) remain unknown.

    Authors: Jiewei Lin, Shuyu Zhai, Siyi Zou, Zhiwei Xu, Jun Zhang, Lingxi Jiang, Xiaxing Deng, Hao Chen, Chenghong Peng, Jiaqiang Zhang and Baiyong Shen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:316
  31. Identification of genomic biomarkers to predict the anticancer effects of indicated drugs is considered a promising strategy for the development of precision medicine. DNA endonuclease MUS81 plays a pivotal ro...

    Authors: Chengguo Li, Qian Shen, Peng Zhang, Tao Wang, Weizhen Liu, Ruidong Li, Xianxiong Ma, Xiangyu Zeng, Yuping Yin and Kaixiong Tao
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:315
  32. Cancer vaccines that induce endogenous antitumor immunity represent an ideal strategy to overcome intractable cancers. However, doing this against a pre-established cancer using autologous immune cells has pro...

    Authors: Kazuhiro Mochizuki, Shogo Kobayashi, Nobuhisa Takahashi, Kotaro Sugimoto, Hideki Sano, Yoshihiro Ohara, Shin Mineishi, Yi Zhang and Atsushi Kikuta
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:314
  33. Trastuzumab-based therapies are the therapeutic option for HER2 positive (HER2+) breast cancer. HER2 amplification is the only biomarker validated for trastuzumab-based therapies. However, a proportion of tumo...

    Authors: Laura Díaz-Gil, Fara Brasó-Maristany, Claudriana Locatelli, Ariana Centa, Balász Győrffy, Alberto Ocaña, Aleix Prat and Atanasio Pandiella
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:313
  34. Acute myeloid leukemia (AML) with mutated nucleophosmin (NPM1), which displays a distinct long noncoding RNA (lncRNA) expression profile, has been defined as a unique subgroup in the new classification of myel...

    Authors: Yipei Jing, Xueke Jiang, Li Lei, Meixi Peng, Jun Ren, Qiaoling Xiao, Yao Tao, Yonghong Tao, Junpeng Huang, Lu Wang, Yuting Tang, Zailin Yang, Zesong Yang and Ling Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:312
  35. The success of antibodies targeting Programmed cell death protein 1 (PD-1) and its ligand L1 (PD-L1) in cancer treatment and the need for improving response rates has led to an increased demand for the develop...

    Authors: Vincent Lemaire, Colby S. Shemesh and Anand Rotte
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:311
  36. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-020-01602-1.

    Authors: Ming-xin Cao, Wei-long Zhang, Xiang-hua Yu, Jia-shun Wu, Xin-wei Qiao, Mei-chang Huang, Ke Wang, Jing-biao Wu, Ya-Jie Tang, Jian Jiang, Xin-hua Liang and Ya-ling Tang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:310
  37. This article has been retracted. Please see the Retraction Notice for more detail: https://doi.org/10.1186/s13046-019-1023-4.

    Authors: Tian-Song Liang, Ying-Juan Zheng, Juan Wang, Jing-Yi Zhao, Dao-Ke Yang and Zhang-Suo Liu
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:309
  38. Kinases play critical role in clear-cell renal cell carcinoma (ccRCC). We aim to exploit novel kinase that is both protumorigenic and drugable in ccRCC.

    Authors: Chenchen Feng, Yuqing Li, Kunping Li, Yinfeng Lyu, Wenhui Zhu, Haowen Jiang and Hui Wen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:308

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2021 40:379

  39. Castration-resistant prostate cancer (CRPC) is associated with a very poor prognosis, and the treatment of which remains a serious clinical challenge.

    Authors: Shangwei Zhong, Ji-Hak Jeong, Changhao Huang, Xueyan Chen, Shohreh Iravani Dickinson, Jasreman Dhillon, Li Yang and Jun-Li Luo
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:307
  40. Radioresistance, a poorly understood phenomenon, results in the failure of radiotherapy and subsequent local recurrence, threatening a large proportion of patients with ESCC. To date, lncRNAs have been reporte...

    Authors: Yuchen Sun, Jizhao Wang, Yuan Ma, Jing Li, Xuanzi Sun, Xu Zhao, Xiaobo Shi, Yunfeng Hu, Fengyi Qu and Xiaozhi Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:306
  41. Kidney cancer is a common urological tumour. Owing to its high prevalence and mortality rate, it is the third most malignant tumour of the urinary system, followed by prostate and bladder cancers. It exerts a ...

    Authors: Weipu Mao, Keyi Wang, Zonglin Wu, Bin Xu and Ming Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:305
  42. Tumor-associated macrophages (TAMs) are key regulators of the complex interplay between cancer and the immune microenvironment. Tumor cell-derived spondin 2 (SPON2) is an extracellular matrix glycoprotein that...

    Authors: Chengmei Huang, Ruizhang Ou, Xiaoning Chen, Yaxin Zhang, Jiexi Li, Yihao Liang, Xiaohui Zhu, Lei Liu, Mingzhou Li, Dagui Lin, Junfeng Qiu, Guanglong Liu, Lingjie Zhang, Yuanyuan Wu, Huiyi Tang, Yanmin Liu…
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:304
  43. The exploitation of novel nanomaterials combining diagnostic and therapeutic functionalities within one single nanoplatform is challenging for tumor theranostics.

    Authors: Lili Ye, Yaoming Chen, Jizong Mao, Xiaotian Lei, Qian Yang and Chunhui Cui
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:303
  44. Chemotherapy remains a standard treatment option for breast cancer despite its toxic effects to normal tissues. However, the long-lasting effects of chemotherapy on non-malignant cells may influence tumor cell...

    Authors: Jana Plava, Monika Burikova, Marina Cihova, Lenka Trnkova, Bozena Smolkova, Pavel Babal, Lucia Krivosikova, Pavol Janega, Lucia Rojikova, Slavka Drahosova, Martin Bohac, Lubos Danisovic, Lucia Kucerova and Svetlana Miklikova
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:302
  45. Cell invasion is a hallmark of metastatic cancer, leading to unfavorable clinical outcomes. In this study, we established two highly invasive lung cancer cell models (A549-i8 and H1299-i8) and identified mesod...

    Authors: Yang Wang, Jing Zhang, Yang-Jia Li, Nan-Nan Yu, Wan-Ting Liu, Jun-Ze Liang, Wen Wen Xu, Zheng-Hua Sun, Bin Li and Qing-Yu He
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:301
  46. The global epidemiological studies reported lower cancer risk after long-term use of contraceptives. Our systematic studies demonstrated that abortifacients are effective in preventing cancer metastases induce...

    Authors: Jie Wang, Xiaobo Yu, Huayi Peng, Yusheng Lu, Shuhui Li, Qing Shi, Jian Liu, Haiyan Dong, Vladimir Katanaev and Lee Jia
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:300

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2021 40:332

  47. Authors: Jing Cai, Mei Yi, Yixin Tan, Xiaoling Li, Guiyuan Li, Zhaoyang Zeng, Wei Xiong and Bo Xiang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:298

    The original article was published in Journal of Experimental & Clinical Cancer Research 2021 40:190

  48. Chemoresistance is the major cause of chemotherapy failure in patients with colorectal cancer (CRC). Protein tyrosine kinase 6 (PTK6) is aberrantly overexpressed in clinical CRC tissues undergoing chemotherapy...

    Authors: Chaoqun Liu, Zhihua Pan, Qian Chen, Zetao Chen, Weiwei Liu, Ling Wu, Muhong Jiang, Wandie Lin, Yujie Zhang, Weihao Lin, Rui Zhou and Liang Zhao
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:297

Annual Journal Metrics

  • 2022 Citation Impact
    11.3 - 2-year Impact Factor
    11.5 - 5-year Impact Factor
    1.870 - SNIP (Source Normalized Impact per Paper)
    2.413 - SJR (SCImago Journal Rank)

    2023 Speed
    4 days submission to first editorial decision for all manuscripts (Median)
    100 days submission to accept (Median)

    2023 Usage 
    3,003,080 downloads
    3,022 Altmetric mentions